TG Therapeutics, Inc. (TGTX) trades at a trailing P/E of 10.8, forward P/E of 25.0. Trailing earnings yield is 9.24%, forward earnings yield 3.99%. PEG 0.01 (Peter Lynch undervalued ≤1.0). Graham Number is $17.86.
Criteria proven by this page:
Overall SharesGrow Score: 84/100 with 5/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -2.9 | -0.18 | 6.36 | 1,496.53 | - |
| 2017 | -4.3 | -0.22 | 7.60 | 3,340.12 | - |
| 2018 | -1.8 | -0.09 | 12.87 | 2,035.62 | - |
| 2019 | -5.7 | 0.38 | 25.40 | 6,453.25 | - |
| 2020 | -21.5 | -0.92 | 11.55 | 39,471.44 | - |
| 2021 | -7.2 | -0.83 | 10.59 | 375.58 | - |
| 2022 | -7.2 | 0.16 | 27.34 | 575.19 | - |
| 2023 | 191.3 | -1.80 | 15.11 | 10.38 | - |
| 2024 | 187.1 | 2.36 | 19.67 | 13.29 | - |
| 2025 | 9.6 | 0.01 | 6.64 | 6.98 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-1.60 | $152.38K | $-78.25M | -51353.4% |
| 2017 | $-1.91 | $152.38K | $-118.48M | -77749.9% |
| 2018 | $-2.30 | $152K | $-173.48M | -114132.9% |
| 2019 | $-2.03 | $152K | $-179.35M | -117991.4% |
| 2020 | $-2.48 | $152K | $-285.88M | -188077.6% |
| 2021 | $-2.69 | $6.69M | $-355.55M | -5315.5% |
| 2022 | $-1.51 | $2.79M | $-203.83M | -7318.9% |
| 2023 | $0.09 | $233.66M | $12.67M | 5.4% |
| 2024 | $0.15 | $329M | $23.38M | 7.1% |
| 2025 | $2.77 | $616.29M | $447.18M | 72.6% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $1.38 | $0.61 – $1.77 | $897.41M | $893.12M – $905.2M | 5 |
| 2027 | $2.27 | $1.68 – $2.80 | $1.14B | $1.08B – $1.19B | 4 |
| 2028 | $2.85 | $1.96 – $3.80 | $1.46B | $1.36B – $1.52B | 4 |
| 2029 | $3.22 | $2.94 – $3.41 | $1.76B | $1.64B – $1.84B | 2 |
| 2030 | $3.92 | $3.57 – $4.15 | $2.04B | $1.9B – $2.14B | 2 |
